Royalty Pharma struck a deal with Neurimmune for a royalty interest tied to cliramitug, a TTR-fibril-depleting antibody in Phase III for transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The agreement includes a $125 million upfront payment for a 3%–4% royalty on worldwide net sales, plus $125 million due in Q1 2027 and $175 million contingent on clinical and regulatory milestones. Cliramitug is evaluated in the Phase III DepleTTR-CM trial (NCT06183931), with results expected in 2028. Neurimmune framed the transaction as funding internal R&D while retaining most royalty and milestone interests, and Royalty Pharma highlighted strong market momentum in ATTR-CM. The structure illustrates how late-stage antibody assets are increasingly financed through royalty monetizations, potentially reshaping capital allocation for development-stage and commercialization-focused teams.